SRPT: חוב להון עצמי sarepta.com

Sarepta Therapeutics, Inc. (SRPT) relies on its monopoly in the treatment of Duchenne muscular dystrophy, backed by robust patent protection. However, business success depends on regulatory verdicts and insurance coverage. On GURU.Markets, the total debt-to-equity chart visualizes these risks; the current ratio is 0.71. Breakthrough genetic products provide the company with a long-term commercial growth cycle and high market valuation.

The total debt-to-equity ratio measures a business's degree of financial autonomy through the ratio of borrowed funds to equity. This metric reflects a company's dependence on creditors and its resilience to market shocks. By analyzing the leverage chart via debt-to-equity, an investor assesses the risk of default or the potential for expansion. For Sarepta Therapeutics, Inc. (SRPT), the balance of liabilities is critical when scaling costly research and development. Scientific authority in gene therapy allows the company to raise capital on favorable terms.